Shaji K. Kumar-rekin lankidetzan egindako argitalpenak (21)

2024

  1. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Disease Monitoring In Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia

2022

  1. Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)

    Advances in Therapy

  2. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284

  3. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  4. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

  5. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

  6. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis

    Advances in Therapy, Vol. 39, Núm. 5, pp. 1976-1992

2021

  1. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

  2. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2019

  1. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 494-503

2018

  1. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

    Blood Cancer Journal, Vol. 8, Núm. 11

2017

  1. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

    Blood, Vol. 130, Núm. 24, pp. 2610-2618

  2. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    The Lancet Oncology, Vol. 18, Núm. 4, pp. e206-e217

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

  2. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma

    Future Oncology, Vol. 11, Núm. 8, pp. 1153-1168

2013

  1. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Leukemia, Vol. 27, Núm. 4, pp. 780-791

2011

  1. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

    Blood

2009

  1. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

    Leukemia, Vol. 23, Núm. 10, pp. 1904-1912